Filing Analysis
Oncolytics Biotech Inc. issued a press release regarding FDA feedback concerning the planned pivotal Part B expansion of its REO 033 colorectal cancer study and other study design elements.
📋 Key Facts
- The company received feedback from the U.S. FDA on August 18, 2026.
- Feedback pertains to the planned pivotal Part B expansion of the REO 033 colorectal cancer study.
- Feedback also covers other planned study design elements.
Oncolytics Biotech Inc. received a notice from Nasdaq stating it is in violation of the $1.00 minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has been granted a compliance period until January 19, 2027, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days, indicating significant downward momentum or lack of investor confidence.
- Risk of delisting if compliance is not achieved within the allotted timeframe.
📋 Key Facts
- Received Nasdaq deficiency letter on July 20, 2026.
- Violation of Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Compliance period granted until January 19, 2027 (180 calendar days).
- To regain compliance, stock must close at or above $1.00 for at least 10 consecutive business days.
- Potential for an additional 180-day extension if certain market value and notification requirements are met.
Oncolytics Biotech Inc. announced that the FDA has granted Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for treating specific squamous cell carcinoma of the anal canal.
📋 Key Facts
- FDA granted Fast Track Designation for pelareorep + checkpoint inhibitor combo.
- Target indication: Inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal.
- Patient population: Those who progressed on or were intolerant to one or more prior lines of systemic therapy.
- Filing date: July 20, 2026.
Oncolytics Biotech Inc. announced progress updates regarding its REO 033 study and an upcoming Type D meeting with the FDA to discuss registrational expansion plans.
📋 Key Facts
- Company issued a press release on July 13, 2026, regarding REO 033 study progress.
- A Type D meeting is planned with the U.S. Food and Drug Administration (FDA).
- The FDA meeting will focus on registrational expansion and study design elements.
Oncolytics Biotech Inc. has disengaged Ernst & Young LLP (EY) and appointed Baker Tilly US, LLP as its independent registered public accounting firm for the 2026 fiscal year due to corporate restructuring. Notably, previous EY reports included explanatory paragraphs regarding the company's ability to continue as a going concern.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language in prior audit reports.
- The company is undergoing 'corporate restructuring', which can sometimes precede significant financial distress or shifts in reporting standards.
📋 Key Facts
- Disengaged Ernst & Young LLP (EY) effective July 6, 2026.
- Engaged Baker Tilly US, LLP for the 2026 fiscal year, subject to client acceptance procedures.
- The change is attributed to a corporate restructuring.
- Previous EY reports for FY2024 and FY2025 contained explanatory paragraphs regarding going concern uncertainty.
Oncolytics Biotech Inc. issued a press release on June 16, 2026, announcing a new patent concerning the manufacturing of pelareorep and providing updates to its intellectual property portfolio.
📋 Key Facts
- The company announced a new patent specifically related to the manufacturing of pelareorep.
- The filing includes updates regarding the broader intellectual property portfolio for pelareorep.
- The information was furnished via a press release (Exhibit 99.1) on June 16, 2026.
Oncolytics Biotech Inc. announced the appointment of John McAdory as Chief Operating Officer and Stephen Glover as a ninth member of the Board of Directors, effective June 1, 2026.
📋 Key Facts
- John McAdory appointed as COO on June 1, 2026; he previously served as EVP of Strategy and Operations since January 2026.
- Stephen Glover appointed as a director on June 1, 2026, bringing extensive biopharma experience including roles at ZyVersa Therapeutics and Ambrx Biopharma.
- Stephen Glover was granted an option to purchase 96,000 shares of common stock, vesting in equal installments of 32,000 shares over three years.
- Mr. McAdory's background includes clinical operations leadership at CG Oncology, Inc. and SillaJen, Inc.
- Mr. Glover's track record includes guiding Ambrx Biopharma through a ~$2 billion acquisition by Johnson & Johnson.
Oncolytics Biotech Inc. issued a press release on June 1, 2026, announcing initial preclinical data for its lead candidate, pelareorep, in combination with RAS inhibitor modalities.
📋 Key Facts
- The company released initial preclinical data for pelareorep combined with RAS inhibitor modalities.
- The company announced plans to conduct additional studies evaluating pelareorep with multiple RAS-targeted agents.
- The filing is categorized under Item 8.01 (Other Events) and the information is 'furnished' rather than 'filed'.
Oncolytics Biotech Inc. announced that it will present translational data from its GOBLET and AWARE-1 clinical studies at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will describe pelareorep's mechanism of action and its effect on the activation of the innate and adaptive immune systems.
📋 Key Facts
- Filing date and event date of May 22, 2026.
- The company will present clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- Data includes translational findings from the GOBLET and AWARE-1 studies.
- The data focuses on pelareorep's mechanism of action and its activation of the innate and adaptive immune systems.
- The announcement was disseminated via a press release filed as Exhibit 99.1.
Oncolytics Biotech Inc. issued a press release on May 4, 2026, providing updates on its REO 022 clinical study. The study focuses on treatments for metastatic colorectal cancer.
📋 Key Facts
- The company announced updates for the REO 022 clinical study on May 4, 2026.
- The study targets metastatic colorectal cancer.
- The disclosure was filed under Item 8.01 (Other Events) and includes a press release as Exhibit 99.1.
- The filing was signed by CFO Kirk Look.
Oncolytics Biotech Inc. announced it has reached an agreement with the U.S. FDA regarding the design of a controlled randomized pivotal study. The study will focus on treating squamous cell carcinoma of the anal canal.
📋 Key Facts
- The company announced FDA alignment on April 27, 2026.
- The planned study is a controlled randomized pivotal trial.
- The target indication is squamous cell carcinoma of the anal canal.
- The announcement was filed under Item 8.01 (Other Events).
Oncolytics Biotech Inc. announced an upcoming Type C meeting with the FDA to discuss the design of a single-arm pivotal study for its lead candidate, pelareorep. The study aims to evaluate pelareorep in combination with a checkpoint inhibitor for the treatment of squamous cell anal carcinoma (SCAC).
📋 Key Facts
- The company has scheduled a Type C meeting with the U.S. FDA.
- The meeting will focus on the design of a single-arm pivotal study for pelareorep.
- The target indication is squamous cell anal carcinoma (SCAC).
- The treatment regimen involves a combination of pelareorep and a checkpoint inhibitor.
- The announcement was made via a press release on April 6, 2026.
Oncolytics Biotech Inc. entered into an Open Market Sale Agreement with Jefferies LLC to establish an At-The-Market (ATM) offering of up to $75.0 million. The company intends to use the proceeds to fund the clinical development of its lead candidate, pelareorep, and for general corporate purposes.
🚩 Red Flags
- Potential for significant shareholder dilution if the full $75.0 million is utilized, which is common for micro-cap biotech firms needing to fund clinical trials.
📋 Key Facts
- Agreement entered into on April 6, 2026, with Jefferies LLC as the sales agent.
- The company may sell common stock with an aggregate offering price of up to $75.0 million.
- Jefferies LLC will receive a commission of up to 3.0% of the gross proceeds from sales.
- The offering is conducted under a shelf registration statement on Form S-3 (File No. 333-294811) effective as of April 3, 2026.
- Proceeds are earmarked for the clinical development of pelareorep, R&D expenses, and working capital.
Oncolytics Biotech completed its redomestication from British Columbia, Canada, to Nevada, USA, effective March 31, 2026. This structural change involved adopting new Articles of Incorporation, Bylaws, and a significantly dilutive 2026 Incentive Award Plan.
🚩 Red Flags
- Significant potential dilution from the 2026 Incentive Award Plan's 6.5 million share pool and 6% annual evergreen increase.
- Implementation of robust anti-takeover measures, including 'blank check' preferred stock and restricted stockholder ability to act by written consent.
- Supermajority requirements (two-thirds) for director removal and bylaw amendments make management changes more difficult.
- Exclusive forum provisions in the new Bylaws restrict litigation to Nevada courts, potentially increasing costs for shareholder claims.
📋 Key Facts
- Completed redomestication from British Columbia to Nevada on March 31, 2026.
- Adopted the 2026 Incentive Award Plan with an initial pool of 6,500,000 shares.
- The 2026 Plan includes an 'evergreen' provision allowing an annual increase of up to 6% of outstanding common stock starting January 1, 2027.
- New CUSIP number 68237V 103 and ISIN US68237V1035 effective April 1, 2026.
- Entered into new indemnification and advancement agreements with all executive officers and directors.
- Governance changes include the authorization of 'blank check' preferred stock and a two-thirds supermajority requirement for stockholders to remove directors or amend bylaws.
Oncolytics Biotech Inc. has initiated a two-step redomestication process, moving its jurisdiction from Alberta, Canada, to British Columbia, Canada, effective March 17, 2026. The company plans to complete the second step by domesticating in Nevada, USA, on March 31, 2026, which will result in a change of governing law and security identifiers.
🚩 Red Flags
- Material modification of shareholder rights as the company moves from Canadian (ABCA/BCBCA) to US (Nevada) corporate law.
- Complex two-step legal restructuring involving multiple jurisdictions in a short timeframe.
📋 Key Facts
- Shareholders approved the redomestication at a Special Meeting on January 15, 2026.
- Step 1: Completed 'Continuance' from Alberta to British Columbia on March 17, 2026.
- Step 2: Planned 'Domestication' to Nevada, USA, scheduled for March 31, 2026.
- Effective April 1, 2026, the CUSIP will change to 68237V 103 and the ISIN to US68237V1035.
- Common shares will transition to Nevada common stock with a par value of $0.001 per share.
- The company's ticker symbol 'ONCY' will remain unchanged on the Nasdaq.
Oncolytics Biotech announced the acceptance of two clinical trial abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting. The presentations will feature data from the GOBLET study in pancreatic cancer and the AWARE-1 study in breast cancer.
📋 Key Facts
- Filing date: March 19, 2026.
- Two abstracts accepted for the AACR Annual Meeting.
- Data includes Cohort 1 of the GOBLET study focusing on metastatic pancreatic ductal adenocarcinoma.
- Data includes the AWARE-1 study focusing on breast cancer patients.
- The filing is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-289819).
Oncolytics Biotech Inc. announced the launch of REO 033, a randomized clinical study evaluating treatments for second-line RAS-mutant microsatellite stable (MSS) metastatic colorectal cancer. The announcement was made via a press release on March 2, 2026, and is incorporated into the company's existing shelf registration.
📋 Key Facts
- Launch of randomized study REO 033 announced on March 2, 2026
- Study targets second-line RAS-mutant microsatellite stable (MSS) metastatic colorectal cancer patients
- Press release attached as Exhibit 99.1
- The filing is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-289819)
Oncolytics Biotech announced a strategic shift to prioritize registrational or registration-enabling studies specifically for colorectal and anal cancer. Concurrently, the company has completed enrollment for its GOBLET gastrointestinal cancer study.
📋 Key Facts
- Prioritizing registrational studies in colorectal and anal cancer
- Concluded enrollment in the GOBLET gastrointestinal cancer study
- Filing is incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-289819)
- Press release dated February 24, 2026
Oncolytics Biotech announced that the FDA has granted Fast Track Designation for its combination therapy (pelareorep, bevacizumab, leucovorin, fluorouracil, and irinotecan) to treat second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer.
📋 Key Facts
- FDA granted Fast Track Designation for a specific drug combination: pelareorep, bevacizumab, leucovorin, fluorouracil, and irinotecan (FOLFIRI).
- Target indication: second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer.
- Announcement date: February 4, 2026.
Oncolytics Biotech Inc. held a Special Meeting of Shareholders on January 15, 2026, where shareholders approved three major proposals including the company's relocation and domestication from Canada to Nevada, USA.
🚩 Red Flags
- Low quorum participation (only 16.35% of total outstanding shares were present or represented by proxy).
📋 Key Facts
- Special Meeting held on January 15, 2026.
- Proposal 1: Continuance from Alberta, Canada to British Columbia, Canada was approved (14,994,075 For / 2,602,405 Against).
- Proposal 2: Domestication from British Columbia, Canada to the State of Nevada, USA was approved (15,304,574 For / 2,291,905 Against).
- Proposal 3: Approval of the 2026 Incentive Award Plan was approved (13,508,657 For / 4,087,822 Against).
- Quorum represented 16.35% of outstanding common shares (17,596,480 shares).
Oncolytics Biotech, Inc. announced the appointment of two new executives to its leadership team on January 14, 2026.
📋 Key Facts
- Appointment of John McAdory as Executive Vice President of Strategy and Operations.
- Appointment of Yujun Wu as Vice President, Head of Biostatistics.
- The announcement was made via a press release dated January 14, 2026.
Oncolytics Biotech, Inc. issued two press releases regarding updates to its intellectual property portfolio and new clinical data for pelareorep in combination with atezolizumab.
📋 Key Facts
- January 8, 2026: Company announced updates on IP status and efforts to extend patent protection for pelareorep.
- January 12, 2026: Company released updated clinical data from GOBLET Cohort 4 regarding pelareorep plus atezolizumab in third-line anal cancer.